- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT00879814
Study Evaluating Safety And Tolerability Of Meningococcal B Rlp2086 Vaccine In Healthy Adults
A Phase 1 Randomized, Open-label, Parallel-group, Active- And Placebo-controlled Study To Assess Safety And Tolerability Of 60, 120, And 200 Mcg Meningococcal Group B Rlp2086 Vaccine In Healthy Adult Subjects
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Studientyp
Einschreibung (Tatsächlich)
Phase
- Phase 1
Kontakte und Standorte
Studienorte
-
-
Florida
-
South Miami, Florida, Vereinigte Staaten, 33143
- Miami Research Associates, Inc.
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
A subject must meet the following inclusion criteria at screening (visit 1) and at randomization (visit 2) to be considered for enrollment in the study:
- Male or female subjects between the ages of 18 and 40.
- Healthy male or female subjects as determined by medical history, physical examination, and judgment of the investigator.
- Male or female subject who is considered biologically capable of having children must agree to commit to the use of a reliable method of birth control for the duration of the study and for 30 days after early discontinuation. A subject is still biologically capable of having children, even if he or she is using contraceptives or if his or her sexual partner is sterile or using contraceptives.
In addition a subject must meet the following inclusion criteria at randomization (visit 2) to be considered for enrollment in the study. The referred blood and urinalysis tests (inclusion criterion 5) will be performed on a blood and urine sample taken at visit 1:
- Female subjects of childbearing potential with a negative urine pregnancy test prior to study drug administration. Note: this criterion will apply to each vaccination visit and to the last study visit.
- Laboratory blood and urinalysis tests results within the per-protocol normal ranges.
- Able to be contacted by telephone during the study period. Note: this criterion will apply to each study visit.
Exclusion Criteria:
None
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Verhütung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
---|---|
Experimental: 1
rLP2086 vaccine 60 mcg
|
intra-muscular vaccine (solution), 0.5 mL, 3 doses, schedule: 0, 2, 6 months
|
Experimental: 2
rLP2086 vaccine 120 mcg
|
intra-muscular vaccine (solution), 0.5 mL, 3 doses, schedule: 0, 2, 6 months
|
Experimental: 3
rLP2086 vaccine 200 mcg
|
intra-muscular vaccine (solution), 0.5 mL, 3 doses, schedule: 0, 2, 6 months
|
Aktiver Komparator: 4
Tdap vaccine - normal saline - normal saline
|
intra-muscular vaccine (solution), 0.5 mL, 3 doses, schedule: 0, 2, 6 months
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Zeitfenster |
---|---|
Percentage of Participants With at Least One Adverse Event (AE)
Zeitfenster: Baseline up to Month 7
|
Baseline up to Month 7
|
Percentage of Participants With Change in Severity From Baseline in Laboratory Evaluations (Alanine Aminotransferase [ALT])
Zeitfenster: Baseline up to Month 7
|
Baseline up to Month 7
|
Percentage of Participants With Change in Severity From Baseline in Laboratory Evaluations (Aspartate Aminotransferase [AST])
Zeitfenster: Baseline up to Month 7
|
Baseline up to Month 7
|
Percentage of Participants With Change in Severity From Baseline in Laboratory Evaluations (Total Protein)
Zeitfenster: Baseline up to Month 7
|
Baseline up to Month 7
|
Percentage of Participants With Change in Severity From Baseline in Laboratory Evaluations (Albumin)
Zeitfenster: Baseline up to Month 7
|
Baseline up to Month 7
|
Percentage of Participants With Change in Severity From Baseline in Laboratory Evaluations (Alkaline Phosphatase [ALP])
Zeitfenster: Baseline up to Month 7
|
Baseline up to Month 7
|
Percentage of Participants With Change in Severity From Baseline in Laboratory Evaluations (Total Bilirubin)
Zeitfenster: Baseline up to Month 7
|
Baseline up to Month 7
|
Percentage of Participants With Change in Severity From Baseline in Laboratory Evaluations (Creatine Phosphokinase [CPK])
Zeitfenster: Baseline up to Month 7
|
Baseline up to Month 7
|
Percentage of Participants With Change in Severity From Baseline in Laboratory Evaluations (Prothrombin Time [PT])
Zeitfenster: Baseline up to Month 7
|
Baseline up to Month 7
|
Percentage of Participants With Change in Severity From Baseline in Laboratory Evaluations (Partial Thromboplastin Time [PTT])
Zeitfenster: Baseline up to Month 7
|
Baseline up to Month 7
|
Percentage of Participants With Change in Severity From Baseline in Laboratory Evaluations (Fibrinogen)
Zeitfenster: Baseline up to Month 7
|
Baseline up to Month 7
|
Percentage of Participants With Change in Severity From Baseline in Laboratory Evaluations (Hemoglobin)
Zeitfenster: Baseline up to Month 7
|
Baseline up to Month 7
|
Percentage of Participants With Change in Severity From Baseline in Laboratory Evaluations (White Blood Cell [WBC])
Zeitfenster: Baseline up to Month 7
|
Baseline up to Month 7
|
Percentage of Participants With Change in Severity From Baseline in Laboratory Evaluations (Lymphocytes)
Zeitfenster: Baseline up to Month 7
|
Baseline up to Month 7
|
Percentage of Participants With Change in Severity From Baseline in Laboratory Evaluations (Neutrophils)
Zeitfenster: Baseline up to Month 7
|
Baseline up to Month 7
|
Percentage of Participants With Change in Severity From Baseline in Laboratory Evaluations (Eosinophils)
Zeitfenster: Baseline up to Month 7
|
Baseline up to Month 7
|
Percentage of Participants With Change in Severity From Baseline in Laboratory Evaluations (Platelet Count)
Zeitfenster: Baseline up to Month 7
|
Baseline up to Month 7
|
Percentage of Participants With Change in Severity From Baseline in Laboratory Evaluations (Sodium).
Zeitfenster: Baseline up to Month 7
|
Baseline up to Month 7
|
Percentage of Participants With Change in Severity From Baseline in Laboratory Evaluations (Potassium).
Zeitfenster: Baseline up to Month 7
|
Baseline up to Month 7
|
Percentage of Participants With Change in Severity From Baseline in Laboratory Evaluations (Blood Urea Nitrogen [BUN]).
Zeitfenster: Baseline up to Month 7
|
Baseline up to Month 7
|
Percentage of Participants With Change in Severity From Baseline in Laboratory Evaluations (Serum Creatinine).
Zeitfenster: Baseline up to Month 7
|
Baseline up to Month 7
|
Percentage of Participants With Change in Severity From Baseline in Laboratory Evaluations (Urine Red Blood Cells [RBC]).
Zeitfenster: Baseline up to Month 7
|
Baseline up to Month 7
|
Percentage of Participants With Change in Severity From Baseline in Laboratory Evaluations (Urine Protein).
Zeitfenster: Baseline up to Month 7
|
Baseline up to Month 7
|
Percentage of Participants With Change in Severity From Baseline in Laboratory Evaluations (Urine Glucose).
Zeitfenster: Baseline up to Month 7
|
Baseline up to Month 7
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Zeitfenster |
---|---|
Meningococcal Immunoglobulin G (IgG) Geometric Mean Titers (GMT)
Zeitfenster: Before Dose 1, 1 month after Dose 2, before Dose 3, 1 month after Dose 3
|
Before Dose 1, 1 month after Dose 2, before Dose 3, 1 month after Dose 3
|
Mitarbeiter und Ermittler
Sponsor
Publikationen und hilfreiche Links
Allgemeine Veröffentlichungen
- Beeslaar J, Mather S, Absalon J, Eiden JJ, York LJ, Crowther G, Maansson R, Maguire JD, Peyrani P, Perez JL. Safety data from the MenB-FHbp clinical development program in healthy individuals aged 10 years and older. Vaccine. 2022 Mar 15;40(12):1872-1878. doi: 10.1016/j.vaccine.2022.01.046. Epub 2022 Feb 11.
- Sheldon EA, Schwartz H, Jiang Q, Giardina PC, Perez JL. A phase 1, randomized, open-label, active-controlled trial to assess the safety of a meningococcal serogroup B bivalent rLP2086 vaccine in healthy adults. Hum Vaccin Immunother. 2012 Jul;8(7):888-95. doi: 10.4161/hv.19983. Epub 2012 Jul 1.
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn
Primärer Abschluss (Tatsächlich)
Studienabschluss (Tatsächlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Schätzen)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Schätzen)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
- Erkrankungen des zentralen Nervensystems
- Erkrankungen des Nervensystems
- Infektionen
- Infektionen des zentralen Nervensystems
- Gramnegative bakterielle Infektionen
- Bakterielle Infektionen
- Bakterielle Infektionen und Mykosen
- Meningitis, bakteriell
- Bakterielle Infektionen des zentralen Nervensystems
- Meningokokken-Infektionen
- Neisseriaceae-Infektionen
- Meningitis, Meningokokken
- Meningitis
- Physiologische Wirkungen von Arzneimitteln
- Immunologische Faktoren
- Impfungen
Andere Studien-ID-Nummern
- 6108A1-1004
- B1971004 (Andere Kennung: Alias Study Number)
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Meningitis, Meningokokken
-
Prof. Elizabeth MillerNovartis VaccinesAbgeschlossenMeningokokken-Meningitis, Serogruppe A | Meningokokken-Meningitis, Serogruppe B | Meningokokken-Meningitis, Serogruppe C | Meningokokken-Meningitis, Serogruppe Y | Meningokokken-Meningitis, Serogruppe WVereinigtes Königreich
-
University Hospital, Strasbourg, FranceAbgeschlossenAseptische MeningitisFrankreich
-
Assiut UniversityUnbekannt
-
Rambam Health Care CampusZurückgezogenGramnegative Meningitis | Posttraumatische bakterielle MeningitisIsrael
-
University Medical Centre LjubljanaHarvard University; University of Ljubljana School of Medicine, Slovenia; Slovenian...Unbekannt
-
University of MinnesotaNational Institute of Neurological Disorders and Stroke (NINDS); Medical Research... und andere MitarbeiterAbgeschlossenKryptokokken-Meningitis | Pilz-MeningitisUganda
-
Charite University, Berlin, GermanyRekrutierungBakterielle Meningitis | Implantatinfektion | Pilz-MeningitisDeutschland
-
Brigham and Women's HospitalAktiv, nicht rekrutierendVorbeugende Immunisierung; MeningitisVereinigte Staaten
-
Matinas BioPharma Nanotechnologies, Inc.University of MinnesotaNoch keine RekrutierungKryptokokken-Meningitis